develops in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection, sexually transmitted diseases and other chronic diseases. Our innovative product line includes both point-of-case rapid tests and traditional ELISA/EIA diagnostic tests.
Calypte also offers a broad range of recombinant proteins and antigens as well as proprietary reagents, buffers, and other specialty products to researchers seeking to develop and optimize immunodiagnostic assays. These unique products are based on technologies developed by Calypte scientists and are used throughout our range of in vitro diagnostic tests.
Founded in 1988, Calypte is a pioneer in non-blood-based HIV antibody testing. We’re the first and only company to earn approval from the U.S. Food and Drug Administration for a urine-based HIV-1 antibody-screening test and supplemental Western blot.* Today, our Aware™ family of rapid oral fluid, blood and urine HIV tests offers unrivalled HIV 1/2 testing flexibility in a non-laboratory setting.
Calypte is also the licensed manufacturer of a unique, quantitative enzyme immunoassay developed by the U.S. Centers for Disease Control and Prevention (CDC) that can discriminate between recent and established HIV-1 infections. Designed for use in epidemiology, the Aware™ BED™ EIA is the only practical way to determine HIV-1 incidence — how quickly HIV is spreading in a given population — rather than prevalence. Since its introduction in 2004 (formerly under the name BED HIV-1 Incidence EIA), the Aware™ BED™ EIA has gained widespread favor with government institutions and HIV intervention programs worldwide as a tool for better allocating resources, measuring program success and targeting HIV hot spots.
Working through a network of national and regional distributors as well as through our on-line Life Sciences web-portal (www.calyptelifesciences.com),
Calypte continues to broaden the reach of its products. We plan to launch a new line of rapid HIV antibody tests in the United States and other developed nations using a novel lateral flow platform technology and are working to complete development of a nucleic acid-based diagnostic testing platform. We also remain committed to bringing new products to developing regions where the need is acute for accurate, innovative HIV testing methods.
To meet this demand with maximum quality and efficiency, we’ve expanded our research and pilot manufacturing capacity in Portland and opened offices in Geneva and the United Arab Emirates. We’ve also added manufacturing capacity through a contract with an ISO-certified manufacturer in Thailand and a managed ISO-certified joint venture in China. Publicly held, Calypte trades on the OTCBB under the symbol “CBMC.”http://www.calypte.com/about-us/